- Home
- ACHC vs HALO Comparison
ACHC vs HALO Comparison
Compare ACHC & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACHC | HALO |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 11.2B |
| IPO Year | 2011 | 2001 |
Fundamental Metrics
Financial Performance| Metric | ACHC | HALO |
|---|---|---|
| Price | $27.65 | $104.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 11 |
| Target Price | $22.67 | ★ $78.64 |
| AVG Volume (30 Days) | ★ 2.5M | 2.2M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.05 | ★ 3.11 |
| Revenue | ★ $3,312,769,000.00 | $151,862,000.00 |
| Revenue This Year | $5.08 | $28.24 |
| Revenue Next Year | $5.98 | $12.56 |
| P/E Ratio | $549.20 | ★ $33.73 |
| Revenue Growth | ★ 5.04 | N/A |
| 52 Week Low | $11.43 | $61.23 |
| 52 Week High | $35.83 | $105.11 |
Technical Indicators
Market Signals| Indicator | ACHC | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 38.92 | 79.75 |
| Support Level | $26.62 | $67.12 |
| Resistance Level | $27.53 | N/A |
| Average True Range (ATR) | 1.62 | 3.47 |
| MACD | -0.45 | 1.26 |
| Stochastic Oscillator | 13.27 | 99.08 |
Price Performance
Historical ComparisonAbout ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Its facilities and services are classified into the following categories: acute inpatient psychiatric facilities; specialty treatment facilities; CTCs; and residential treatment centers. In which Acute inpatient psychiatric facilities contribute the majority of revenue in the United States. The Company has one reportable segment, behavioral healthcare services. The behavioral healthcare services segment provides inpatient and outpatient behavioral healthcare services.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.